Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rat models as tool to develop new immunotherapies.

H Link1, B G Xiao

  • 1Division of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.

Immunological Reviews
|March 29, 2002
PubMed
Summary

Dendritic cell (DC) immunotherapies show promise for treating ongoing autoimmune diseases like multiple sclerosis (MS) and myasthenia gravis (MG). Modifying DCs with specific cytokines effectively suppresses established experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune myasthenia gravis (EAMG) in rats.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells.

Multiple sclerosis (Houndmills, Basingstoke, England)·2007
Same author

Immunopathogenesis and prevention of uveitis with the Behçet's disease-specific peptide linked to cholera toxin B.

Advances in experimental medicine and biology·2003
Same author

Bone marrow-derived dendritic cells from experimental allergic encephalomyelitis induce immune tolerance to EAE in Lewis rats.

Clinical and experimental immunology·2001
Same author

Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.

Clinical and experimental immunology·2001
Same author

Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system.

International immunopharmacology·2001
Same author

SIN-1, a nitric oxide donor, ameliorates experimental allergic encephalomyelitis in Lewis rats in the incipient phase: the importance of the time window.

Journal of immunology (Baltimore, Md. : 1950)·2001

Area of Science:

  • Immunology
  • Neuroimmunology
  • Autoimmune Diseases

Background:

  • Rat models, experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune myasthenia gravis (EAMG), mimic human multiple sclerosis (MS) and myasthenia gravis (MG).
  • These models are crucial for evaluating immunotherapeutic strategies for autoimmune conditions.

Purpose of the Study:

  • To investigate the efficacy of different immunotherapeutic strategies, including mucosal tolerance and dendritic cell (DC)-based approaches, in ameliorating ongoing autoimmune diseases in rat models.
  • To identify the most promising DC-based immunotherapies for treating established EAE and EAMG.

Main Methods:

  • Administration of autoantigen via mucosal tolerance (oral/nasal).
  • Nasal administration of cytokines (IL-4, IL-10, TGF-beta1).

Related Experiment Videos

  • In vitro pulsing of DCs with autoantigen.
  • In vitro modification of DCs with cytokines (IFN-gamma, TGF-beta1, IL-10) followed by subcutaneous administration.

    • Main Results:

    • Mucosal tolerance and cytokine administration were ineffective in ongoing rat EAE and EAMG.
    • In vitro autoantigen-pulsed DCs mediated peripheral tolerance but did not affect ongoing disease.
    • Subcutaneous administration of DCs modified with IFN-gamma or TGF-beta1 suppressed ongoing EAE and EAMG.
    • DCs modified with IL-10 inhibited ongoing rat EAMG.

    Conclusions:

    • Different strategies exist to influence T- and B-cell responses in EAE and EAMG.
    • DC-based immunotherapies, particularly those modified with cytokines, are the most promising for ameliorating ongoing organ-specific autoaggressive immunity.
    • Autologous, cytokine-modified DCs offer a basis for novel immunotherapeutic strategies in MS, MG, and other autoimmune diseases.